Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Cellular and Molecular Biology (Noisy-Le-Grand, France)|December 10, 1998
Advanced glycated albumin impairs protein degradation in the kidney proximal tubules cell line LLC-PK1K Sebeková, R Schinzel, H Ling, et al.
Clinical Pharmacology and Therapeutics|April 4, 2013
Gatekeepers and enablers: how drug regulators respond to a challenging and changing environment by moving toward a proactive attitudeF Ehmann, M Papaluca Amati, T Salmonson, et al.
Journal of Cancer Research and Clinical Oncology|August 27, 1998
Renal cell cancer correlated with occupational exposure to trichloroetheneS Vamvakas, T Brüning, B Thomasson, et al.
The Journal of Experimental Medicine|November 1, 1996
Decreased tumor surveillance in perforin-deficient miceM E van den Broek, D Kägi, F Ossendorp, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2015
Early market access of cancer drugs in the EUJ Martinalbo, D Bowen, J Camarero, et al.
Regulatory Toxicology and Pharmacology : RTP|January 27, 1998
Proposed changes in the classification of carcinogenic chemicals in the work areaH G Neumann, H W Thielmann, J G Filser, et al.
Journal of Cancer Research and Clinical Oncology|January 8, 1999
Changes in the classification of carcinogenic chemicals in the work area. (Section III of the German List of MAK and BAT values)H G Neumann, H W Thielmann, J G Filser, et al.
International Archives of Occupational and Environmental Health|December 22, 1998
Changes in the classification of carcinogenic chemicals in the work area. Section III of the German List of MAK and BAT ValuesH G Neumann, S Vamvakas, H W Thielmann, et al.
Clinical Pharmacology and Therapeutics|February 12, 2015
The future is now: model-based clinical trial design for Alzheimer's diseaseK Romero, K Ito, J A Rogers, et al.
Clinical Pharmacology and Therapeutics|February 12, 2015
From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patientsH-G Eichler, L G Baird, R Barker, et al.
Pageof 7